Cyclooxygenase (COX) is a key enzyme in arachidonic acid metabolism. Two isoforms of this enzyme have been identified: constitutive COX-1 and inducible COX-2. Recently, expression of COX-2 has been found in several human carcinomas. COX-2 expression may contribute to the synthesis of prostanoids, which relate to carcinogenesis and tumor progression. We investigated the expression of COX-2 in 175 human esophageal squamous cell carcinoma tissues using immunohistochemistry and evaluated the relationship with clinicopathological findings. In addition, due to the known relevance of p53 to carcinogesis, we evaluated the expression of COX-2 and p53. Interestingly, cancer tissues with high COX-2 expression were found significantly more often in the middle and lower esophagus than in the cervical and upper esophagus (p = 0.0014). No significant differences were observed in other clinicopathological data such as age, sex, histopathological grading, lymphatic invasion, venous invasion, TNM clinical classification and patient prognosis. p53 expression was associated with the expression of COX-2 (p = 0.0122). Our findings suggest that COX-2 may play a role in the development of squamous cell carcinoma in the lower part of the thoracic esophagus.
Introduction
Multiple epidemiological studies have shown that nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin reduce the risk of gastrointestinal cancer [1] . NSAIDs were shown to decrease chemically induced colorectal carcinomas in rodents [2] . In patients with familial adenomatous polyposis, administration of NSAIDs reduced the number and size of colorectal adenomas [3, 4] . Epidemiological studies indicated that NSAIDs decreased the relative risk of esophageal, gastric, and colorectal carcinomas. The main target of NSAIDs is cyclooxygenase (COX), the rate-limiting enzyme in the conversion of arachidonic acid to prostaglandin H 2 . Two isoforms of this enzyme have been identified: COX-1 is constitutively expressed in most tissues and is involved in the physiological production of prostaglandins for maintaining normal physiological functions; COX-2 is involved in inflammation and has been shown to be induced by mitogens, cytokines, hormones, growth factors and overexpression of protein kinase C (PKC) [5] . It has also been reported that COX-2 mRNA and protein, but not COX-1, are markedly elevated in human gastrointestinal cancers compared with normal mucosa and chemically induced rat colon cancer [6] [7] [8] [9] . In addition, Oshima et al. [10] have recently reported that null mutation of COX-2 gene is associated with a dramatic decrease in the number and size of intestinal polyps in Apc ¢716 knockout mice, a model of human familial adenomatous polyposis, which suggests that COX-2 is important in tumor formation. Treatment with COX-2-selective inhibitors also reduced the number of intestinal polyps in Apc ¢716 knockout mice. The exact relationship between the induction of COX-2 and carcinogenesis in tumor proliferation is uncertain, though there are several reports concerning this linkage. Prostaglandins, which are produced by the catalytic reaction of COX, may act as tumor promoters, causing cell proliferation, tumor angiogenesis and inhibition of immune surveillance [11] [12] [13] . COX-2 overexpression causes the development of altered cellular adhesion to extracellular matrix and resistance to apoptosis in intestinal epithelial cells [14] and is associated with increased levels of angiogenic factors in colon cancer cells [15] . Zimmermann et al. [16] have recently reported in a pathological investigation that esophageal cancer also frequently expresses COX-2 [16] . With regard to esophageal carcinogenesis, p53 mutation is known to be the most important factor [17] , and a recent paper suggested that COX-2 expression is also associated with p53 mutation [18] .
In this study, we examined COX-2 expression in human esophageal squamous cell carcinoma using immunohistochemical staining and evaluated the relationship with pathological findings, clinical observations and p53 expression. For confirmation of the protein level of COX-2, we performed Western blot analysis on esophageal squamous cell carcinoma tissue and adjacent normal esophageal mucosa.
Materials and Methods

Clinical Materials
Tissues were obtained from esophageal squamous cell carcinoma specimens of 175 patients who underwent esophagectomies at our institution between June 1987 and December 1997. The operation techniques used were as previously described [19] . In brief, esophagectomy with lymph node dissection was performed through a right thoracotomy, and subsequent reconstitution was carried out mostly by means of an esophagogastrostomy using a gastric tube through the retrosternal route. The ages of the patients ranged from 39 to 84 years; 146 were males (average age 63.7 years), 29 were females (average age, 66.5 years). These resected tumors were microscopically examined to identify histologic type, extent and mode of cancer invasion, and lymph node metastasis. One hundred and sixty-seven patients received curative resection and tolerated the operation. All specimens were fixed in a 10% formaldehyde solution and embedded in paraffin for immunohistochemical analysis. In addition, some of these esophageal squamous cell carcinoma specimens and paired samples of esophageal mucosa, containing no macroscopic tumor tissue or histologically detectable cancer cells, were stored in liquid nitrogen for immunoblotting analysis.
The patients' condition was followed up every 1 or 2 months following their operation.
Immunohistochemical Staining
Immunohistochemical staining was performed using the avidinebiotin method. Tissue sections were deparaffinized and rehydrated in water. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide for 30 min. Sections were rehydrated and washed with phosphate-buffered saline (PBS) and incubated with a blocking reagent, 5% normal horse serum with 1% bovine serum albumin in PBS, for 30 min at room temperature to block nonspecific antibody reactions. Sections were incubated overnight at 4°C with antihuman COX-2 monoclonal antibody (Cayman Chemical Co., Ann Arbor, Mich., USA) and antihuman p53 monoclonal antibody (DO-7, Dako, Tokyo, Japan) in the above-mentioned blocking reagent. After four rinses in PBS, sections were incubated for 2 h at room temperature with biotinylated antimouse immunoglobulin G, followed by four washes with PBS, and reacted with an avidin-biotin system, using 0.03% 3,3)-diaminobenzide tetrahydrochloride for about 3 min as a chromogen. Sections were counterstained with Mayer's hematoxylin.
For positive controls, sections of colon cancer expressing the COX-2 protein were included in each staining procedure [20] . For negative controls, blocking reagent without primary antibody was used as a substitute for the COX-2 and p53 antibody. As additional controls, we also performed preabsorption of primary antibody with pure antigen and demonstrated disappearance of the immunoreactivity.
Evaluation of Immunostaining
Specimens were considered immunopositive for COX-2 when 61% of the tumor cells had clear evidence of immunostaining. The percentage of positive tumor cells was graded as follows: 0 = none; 1 = 1-24%; 2 = 25-49%; 3 = 50-74%; 4 = 75-100%. Immunostaining intensity was rated as follows: 0 = none; 1 = weak; 2 = moderate; 3 = intense. Smooth muscle cells within the esophageal wall provided an internal control. In addition, an immunoreactive score was calculated by multiplication of the percentage of positive cells and staining intensity as reported previously [16, 21] . For example, a specimen containing 40% COX-2 immunopositive tumor cells with strong intensity received a score of 2 ! 3 = 6. In the case of heterogeneous staining intensities within a sample, each component was scored independently, and the results were summed.
The samples were regarded to be positive for p53 if 10% of the cells had a stained nucleus, as previously reported [22] .
Western Blotting
Tissues were homogenized in the sample buffer (0.5 M Tris-HCl, 2% SDS, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride). Lysates were sonicated for 20 s on ice and centrifuged at 14,000 rpm for 20 min to remove the cell debris. The total protein of the supernatant was measured using a BCA protein assay kit (Pierce, Rockford, Ill., USA) with bovine serum albumin as a standard. ß-Mercaptoethanol was added (final concentration was 0.24 M ) to the supernatants, and the samples were boiled for 5 min and analyzed. Thirty micrograms of protein was loaded per lane and SDS-polyacrylamide gel electrophoresis was performed under reducing conditions on 10% polyacrylamide gels as described by Laemmli [23] . Proteins were electrophoretically transferred to PVDF membranes. The PVDF membrane was then incubated with mouse monoclonal anti COX-1, COX-2 antibody (Cayman Chemical Co., Ann Arbor, Mich., USA). The blots were probed with the corresponding secondary antibody to IgG conjugated to alkaline phosphatase. Blots were probed with the BCIP/NBT alkaline phosphatase substrate kit (Vector Laboratories, Burlingame, Calif., USA) according to the manufacturer's instructions. COX-1 and COX-2 standard were purchased from Cayman Chemical Co. and Oxford Biochemical Research, Inc. (Oxford, Mich., USA), respectively. As confirmation that the samples used in Western blot were derived from esophageal mucosa and esophageal carcinoma tissues, membrane was also probed with anti-keratin monoclonal antibody mixture AE1/AE3 (Dako, Tokyo, Japan) as an epithelial marker. KYSE170, an esophageal squamous carcinoma cell line which we have established, was used for positive control.
Statistical Analysis
Relationships between immunostaining results of COX-2 and clinical factors or immunostaining results of p53 were statistically analyzed using the ¯2 test and Fisher's exact test. Survival curves of the patients were calculated using the Kaplan-Meier method and analyzed using the generalized Wilcoxon test. Differences with p ! 0.05 were accepted as statistically significant. Cox's proportional hazard model was used for multivariate analysis. Statview J-4.5 (Abacus Concepts Inc, Berkeley, Calif., USA) was used for statistical analysis.
Results
Expression of COX-2 in Esophageal Squamous Cell Carcinoma
Immunohistological staining with COX-2-specific monoclonal antibody mainly showed cytoplasmic and nuclear membrane staining in the cancer cells ( fig. 1a, b) ; COX-2 was also weakly expressed in inflammatory mononuclear cells, fibroblasts of surrounding stroma ( fig. 1b) , smooth muscle cells and the basal layer of the normal mucosa. One hundred and fifty-two of the 175 cases were positive for COX-2 protein (86.9%) in the tumor cells; 23 cases (13.1%) were completely negative. The immunoreactive score ranged between 0 and 12 and the mean score was 5.25. Table 1 shows the expression patterns of the percentage of positive cells, staining intensity and immunoreactive score. Negative control reactions of COX-2 were carried out with preabsorption of COX-2 antibody with pure COX-2 antigen in the same sample and demonstrated disappearance of the COX-2 immunoreactivity ( fig. 1c) .
As confirmation of the immunohistochemical staining results, we performed Western blot analysis for COX-2 protein. We selected the cases which had both normal mucosa and tumor; there were 2 immunohistochemically low-expression cases and 3 high-expression cases. Figure 2a shows significantly higher levels of COX-2 protein in high-expression esophageal carcinoma (scores 9, 12 and 8) than in low-expression tumors (scores 1 and 0) and Immunohistochemical staining of COX-2 in esophageal squamous cell carcinoma. Specimens were fixed in 10% formaldehyde and embedded in paraffin. An avidin-biotin complex immunoperoxidase method was performed to detect COX-2 using anti-COX-2 monoclonal antibody. a Intense expression of COX-2 was seen in carcinoma tissue (white arrow). Original magnification. !100. b Stained COX-2 appears as granules in cytoplasm of carcinoma cells (white arrow). COX-2 was also expressed in inflammatory mononuclear cells (stripe arrow) and fibroblasts of surrounding stroma (black arrow). Original magnification. !400. c Negative control reactions of COX-2 were carried out with preabsorption of COX-2 antibody with pure COX-2 antigen in the same sample and demonstrated disappearance of the COX-2 immunoreactivity (black arrow). Original magnification. !100.
Kawabe/Shimada/Uchida/Maeda/Sato/ Itami/Imamura paired normal esophageal mucosa by Western blot analysis. These findings were consistent with the results of the immunostainings. The membrane was also probed by COX-1 monoclonal antibody and the protein was evident in all samples. COX-1 expression was not dependent on COX-2 expression or the origin of the tissues (fig. 2b) . As all samples expressed the epithelial marker cytokeratin AE1/AE3, it was concluded that all samples were derived from esophageal epithelial or esophageal carcinoma tissues ( fig. 2c ). 
Correlation between the Expression of COX-2 and Clinicopathological Findings
To evaluate the association between COX-2 expression and clinicopathological findings, samples were divided into low-expression (scores 0-5) and high-expression (scores 6-12) COX-2 immunoreactivity. The mean immunoreactive score was taken to be the cut-off score. Table 2 shows the correlation between the expression of COX-2 and the clinicopathological findings. COX-2 high-expression carcinoma tissues were found significantly more often in the middle and lower esophagus (below the tracheal bifurcation) than in the cervical and upper esophagus (p = 0.0014). There were no correlations between COX-2 expression and other clinicopathological findings such as sex, age, histopathological grading, lym- To evaluate the relation between COX-2 expression and the overall survival rate of patients, patients who received noncurative resection (n = 14) and died from non-cancer-related causes (n = 12) were omitted. Then, 149 of 175 patients were analyzed. The outcome of the patients did not differ depending on COX-2 expression by the Kaplan-Meier method (p = 0.3806, fig. 3 ). Analysis by Cox's hazard model also revealed that COX-2 expression had no impact on the prognosis of the patients.
Association between the Expression of COX-2 and p53
Immunohistochemical staining for p53 in esophageal squamous cell carcinoma tissue revealed intense nuclear staining in tumor cells. Positive rate of p53 expression was 41.7% (73/175).
Due to the known relevance of p53 to carcinogenesis, we evaluated the relation between the expression of COX-2 and p53. Subbaramaiah et al. [18] reported that wildtype p53 caused nearly complete suppression of COX-2 protein expression, whereas mutant p53 did not affect the levels of COX-2 in mouse embryo fibroblast by Western blot analysis. In our study, samples were divided into negative (score = 0) and positive (scores 1-12) COX-2 immunoreactivity and evaluated. There was a significant association between COX-2 and p53 (p = 0.0122, table 3). COX-2 negative expression carcinoma tissues were found significantly more often in p53-negative than in p53-positive cases. If the cut-off value of COX-2 was same as p53 (percentage of positive tumor cells 610%), significant association was also revealed between COX-2 and p53 (p = 0.0023, data not shown).
Discussion
Recently, expression of COX-2 in various kinds of malignant tumors has been reported. Zimmermann et al. [16] reported that they observed COX-2 expression in 91% of esophageal squamous cell carcinoma and in 78% of esophageal adenocarcinoma by immunohistochemical analysis. They also investigated the relation between COX-2 expression and pathological findings such as pT and pN categories. However, they did not include other clinicopathological data, such as sex, tumor location, lymphatic invasion, venous invasion and prognosis, which are considered important in understanding the role of COX-2 in vivo. We found that 152 of 175 esophageal cancers (86.9%) expressed COX-2 protein by immunohistochemical staining. COX-2 high-expression carcinoma tissues were found significantly more often in the middle and lower esophagus (below the tracheal bifurcation) than in the cervical and upper esophagus. In the case of colon cancer, Fujita et al. [24] reported that the COX-2 index was not affected by tumor location. This result is different from our findings in esophageal squamous cell carcinoma. We are not able to explain the differences of the expression of COX-2 in tumor location. But we speculate that one of the reasons for this difference may be the reflux of the gastroduodenal contents into the esophagus. In Barrett's epithelium, which arises in response to chronic injury by reflux esophagitis, and associated adenocarcinoma, there were higher COX-2 mRNA levels and protein expression than in normal control tissues [25] . For example, bile acids, especially dihydroxy bile acid, are known Fig. 3 . Relation between the influence of COX-2 and survival rate. Survival curves of the patients were calculated using the KaplanMeier method. Patients who received noncurative resection (n = 14) and died from non-cancer-related cases (n = 12) were omitted from the calculations. 149 of 175 patients were analyzed. to activate PKC [26] [27] [28] , and overexpression of PKC-i ncreases COX-2 protein [5] . It is therefore conceivable that bile acids may induce COX-2. Furthermore, Zhang et al. [29] reported that dihydroxy bile acids upregulate the expression of COX-2 mRNA and protein in human esophageal adenocarcinoma cells and enhance the production of prostaglandin E2. It is likely that the distal esophagus is more exposed to the gastroduodenal contents than the cervical and upper esophagus because of its location. Besides Barrett's esophagus and adenocarcinoma, squamous cell carcinoma has also been suggested to be correlated with reflux esophagitis [30] [31] [32] . In animal experiments, esophageal cell proliferation increased in the biliopancreatic and pancreatic reflux model [33] and Miwa et al. [34] reported that reflux of duodenal or gastroduodenal contents in rat models induced esophageal adenocarcinoma, adenosquamous carcinoma and squamous cell carcinoma. Ottignon and Deschamps [35] reported that patients with both erosive and nonerosive reflux esophagitis exhibit increased levels of PGE 2 , PGF 2· and PGD 2 in esophageal mucosa derived from endoscopic pinch biopsies compared to healthy controls. However, they did not refer to COX-2 expression in these samples. We did not evaluate COX-2 expression in a large number of samples of normal squamous mucosa adjacent to tumors or normal esophageal mucosa from persons with or without reflux esophagitis. Therefore, further studies are needed to determine the relationship between duodenogastroesophageal reflux and COX-2 expression in esophageal squamous cell carcinoma as well as normal esophageal epithelium. Further determination of the reasons for this variation of COX-2 expression with tumor location is necessary. Other clinicopathological findings such as age, sex, histopathological grading, lymphatic invasion, venous invasion, and TNM pathological classification were not correlated with COX-2 expression. Fujita et al. [24] reported that COX-2 mRNA levels were significantly higher with larger tumor size and deeper invasion in colorectal carcinomas. In our present study of esophageal squamous cell carcinoma, depth of invasion was not correlated with COX-2. However, we consider that the discrepancy between these observations is not due to differences in the organs but differences in the method of experimentation. Although our samples were squamous cell carcinoma, immunoreactivity of COX-2 was often increased in deeper invasion sites. This finding is consistent with previous reports on colorectal and lung carcinoma [24, 36] . It also suggests that increased COX-2 expression may be associated with tumor progression in esophageal carcinoma.
Subbaramaiah et al. [17] reported that wild-type p53 causes a marked decrease in the expression of COX-2 protein and mRNA in mouse embryo fibroblast cell lines. It is conceivable that p53 mutation cannot suppress COX-2 induction and leads to carcinogenesis. We also investigated the association between the expression of COX-2 and p53 in esophageal cancer and found a significant association between the two proteins. Most COX-2-negative cases (82.6%, 19/23) were negative for p53 expression. This result is consistent, in part, with their report. In turn, 81.4% of p53-negative cases expressed COX-2 protein. We think that there are other factors that enhance COX-2 expression in wild-type p53 tumors in vivo.
In conclusion, we found frequent expression of COX-2 in esophageal squamous cell carcinoma. Moreover, COX-2 high-expression cancer tissues were found significantly more often in the middle and lower esophagus than in the cervical and upper esophagus, and COX-2 along with p53 mutation plays an important role in esophageal carcinogenesis. This may prove helpful in the analysis of carcinogenesis of esophageal cancer and the chemopreventive effect of COX-2-selective inhibitors.
